MedPath

“AN OBSERVATIONAL STUDY OF HIGH FLOW NASAL OXYGEN THERAPY IN COVID 19 PATIENTS ADMITTED IN INTENSIVE CARE UNITâ€

Not yet recruiting
Conditions
Coronavirus as the cause of diseases classified elsewhere,
Registration Number
CTRI/2020/12/029563
Lead Sponsor
Not applicable
Brief Summary

This is an observational study of  the utility of HFNO therapy in managing respiratory failure in moderate to severe COVID 19 patients who are admitted in intensive care unit and also to identify the early predictors of HFNO failure.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

1.Patients between age 18-60years 2.Both males and females 3.Patients with type 1 respiratory failure 4.Patients with SpO2 less than or equal to 92% on room air 5.Patients with or without co morbidities.

Exclusion Criteria
  • 1.Patient’s refusal for HFNO 2.Patients below 18years and above 60years 3.
  • Patients with tracheostomy 4.
  • Patients with Claustrophobia 5.Patients with urgent need for endotracheal intubation 6.Patients with GCS less than 8 or raised intracranial tension 7.Patients with upper airway obstruction 8.
  • Pregnant patients.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Whether high flow nasal oxygen therapy can treat hypoxia in COVID 19 patientsDuring ICU stay
Secondary Outcome Measures
NameTimeMethod
1.To analise failure rate of high flow nasal oxygen therapy in COVID 19 patients and escalation to invasive and non-invasive ventilation.during ICU stay

Trial Locations

Locations (1)

St George Hospital

🇮🇳

Mumbai, MAHARASHTRA, India

St George Hospital
🇮🇳Mumbai, MAHARASHTRA, India
DrAshwin sonkamble
Principal investigator
9850961196
seeashwin@rediffmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.